Related Experiment Video
Updated: Jun 11, 2025
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Genomic landscape and preclinical models of angiosarcoma
Annaleigh Benton1,2, Bozhi Liu1,2, Lauren E Gartenhaus1,2
1Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Abstract:
Angiosarcoma is a cancer that develops in blood or lymphatic vessels that presents a significant clinical challenge due to its rarity and aggressive features. Clinical outcomes have not improved in decades, highlighting a need for innovative therapeutic strategies to treat the disease. Genetically, angiosarcomas exhibit high heterogeneity and complexity with many recurrent mutations. However, recent studies have identified some common features within anatomic and molecular subgroups. To identify potential therapeutic vulnerabilities, it is essential to understand and integrate the mutational landscape of angiosarcoma with the models that exist to study the disease. In this review, we will summarize the insights gained from reported genomic alterations in molecular and anatomic subtypes of angiosarcoma, discuss several potential actionable targets, and highlight the preclinical disease models available in the field.
Insights
Angiosarcoma, a rare vascular cancer, has poor outcomes due to its aggressive nature and genetic complexity. Understanding its mutational landscape and available models is key to developing new therapies.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Angiosarcoma is a rare and aggressive cancer originating in blood or lymphatic vessels.
- Current treatments offer limited improvement, necessitating novel therapeutic strategies.
- High genetic heterogeneity complicates understanding and treatment of angiosarcoma.
Purpose of the Study:
- To review genomic alterations in angiosarcoma subtypes.
- To identify potential therapeutic targets.
- To highlight existing preclinical models for angiosarcoma research.
Main Methods:
- Comprehensive literature review of genomic alterations in angiosarcoma.
- Analysis of molecular and anatomic subtypes.
- Evaluation of preclinical models for therapeutic vulnerability assessment.
Main Results:
- Angiosarcomas display significant genetic heterogeneity but share common features within subgroups.
- Specific actionable targets have been identified through genomic profiling.
- Various preclinical models exist for studying angiosarcoma biology and testing therapies.
Conclusions:
- Integrating genomic data with disease models is crucial for identifying therapeutic vulnerabilities.
- Targeting identified pathways may offer new treatment avenues for angiosarcoma.
- Further research utilizing preclinical models is essential for advancing angiosarcoma treatment.
